iBio Stock

iBio (AMEX: IBIO), a business in the healthcare sector, specializes in plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical products. Its products are mainly used in combating fibrotic diseases, cancer and infectious diseases. iBio mainly operates in the segments of biologic development and licensing actions and contract development and manufacturing organization (CDMO).

IBIO Stock Price

The iBio stock price has the potential for an increase due to a ramp up of new biological product developments. As of Sep. 2021, iBio has had an FY21 earnings per share (EPS) of $0.12, up from $0.61 year over year, and sales of $2.37 million up from $1.64 million year over year. It is currently operating at a range of $0.94 to $0.99, a 52-week range of $0.9 to $2.83, and a market cap of $209.4 million. Cantor Fitzgerald suggested iBio stock price target in January 2021 of $3. Looking at the trading performance of iBio stock, the stock has been downgraded to bearish by analysts and is at high risk of performing badly. 

IBIO Stock Forecast

iBio operates with no direct competitors within the healthcare sector due to its niche in the sector. A stock price target of $3.00 from Cantor Fitzgerald would give iBio an increase of 211.33% in price per share. The current analyst recommendation is to consider purchase of the stock given its expected price target and its increase per share percentage. However, the stock has had a negative EPS revision as well as decelerating momentum in comparison with other healthcare stocks. Its Q3 EPS were $0.04, and iBio reported sales of $765,000, which missed the estimate of $800,000 for the quarter. However, multiple opportunities exist for iBio stock to increase due to a series of new ventures within the company. 

IBIO Stock News

iBio has secured an exclusive licensing agreement with RubrYc Therapeutics for RTX-003, which is an immunotherapy candidate targeting regulatory T cells. Regulatory T cells aid the body in the production of stem cells from bone marrow, as well as being an essential component of the immune system. This agreement offers a potential upside given this important area that could have applications for cancer treatments for example. 

iBio plans on using this partnership to advance anti-CD25 antibody RTX-003 as IBIO-101 in a Phase 1 trial. The partnership also grants iBio the ability to license additional antibodies built using RubrYc’s artificial intelligence-based antibody discovery platform, which grants iBio a unique position to leverage the software for further product development. However, this partnership mandated that iBio pay $5 million upfront and an additional $2.5 million in December 2021. iBio will acquire an equity stake in RubrYc. 

Earlier this year, iBio added 3 additional anti-cancer targets to its portfolio of therapeutic candidates. iBio seeks to change the drug development paradigm with its FastPharming System by reducing the time and cost to move from concept to product trial testing. 

"We believe combining our 'speed-to-clinic' advantages and Glycaneering Technologies with the antibody optimization technologies provided by FairJourney may enable us to quickly develop differentiated cancer therapeutic antibodies with improved antibody-dependent cell-mediated cytotoxicity, or ADCC," said Martin B. Brenner, iBio's Chief Scientific Officer.

How to Buy iBio Stock

If you’d like to buy iBio stock, here’s how. If you’ve never purchased a share of stock, the first thing to do is open a brokerage account. Numerous trading platforms allow you to open an account, fund your trades and complete your orders. 

Follow these simple steps to find the best brokers and get started. 

Step 1: Pick a brokerage.

A broker is a financial service provider that is authorized to buy and sell shares of stock on behalf of retail customers. The broker you choose determines how much you pay in commissions on every trade, what platform you use and what type of investments you can buy and sell. Also included are various analysis tools that can aid in your transactions. If you’re unsure of which broker to go with and are lost on where to go, consider looking at some of Benzinga’s favorites below.

Step 2: Decide how many shares you want.

The next step is deciding how many shares you’d like to buy. A rule of thumb is not to feel pressured into buying more than what you're comfortable spending, especially on your first few trades. While you develop your trading strategy, this rule will be helpful. Remember as well that you can start out with just buying a single share then eventually buy more in the future. 

Say you only have a limited amount of money to invest initially; it is possible to start by buying a fractional share of stock. This fractional share is a portion of a whole single share. 

A good broker will allow you to invest fractionally. The brokerage trading platform accomplishes this by placing a limit based on your investment budget and automatically computing the number of shares you can buy with your current capital.  

Step 3: Choose your order type.

Once you’ve calculated how many shares you’d like to purchase, the next choice is deciding on which type of order you would like to use to complete your purchase. The choice made will confirm the details of the order, how much you’ll pay per share and when the order will be completed. 

Before placing your first order, learn these market concepts.

• Market order: This type of order executes as soon as possible at the price that is currently in the market. It allows your order to be filled quickly; however, it can cause you to pay more than anticipated for each share if prices are changing. 
• Stop order: A stop order executes when a stock rises above its lowest price by a set amount. For example, you state in your order that you’ll buy 10 shares of iBio when the stock price increases by 6% above the lowest price of the day. 
• Limit order: This order takes place when shares reach a specific price or fall below that price. Say you want to buy 100 shares of iBio stock at a limit price of $5. The order will only be fulfilled by the broker if each share falls to $5 or less. 
• Stop-loss order: Stop-loss orders automatically exit your position at either a predetermined price or anything lower.
• Stop-limit order: This order is a combination of both a stop and limit order. When you place this type of order, you’ll set a lower stop price and a higher limit price; those act as the boundaries on which the purchasing of a share takes place. If the stop price is met, then the order switches to a limit order. If the market price rises above the limit price, the broker stops the fulfillment of your order. 

Step 4: Execute your trade. 

When filing a trade request, double-check that all the order details are correct. At that point, the broker follows the exact instructions that you send in. If something is incorrect, that error falls on you, so another good rule is to check your order details. If the order goes through properly, you will receive a message verifying it is completed, and your portfolio will show the shares. 

Best Online Stock Brokers for IBIO Stock

Now that you have an overall idea of how trading works, you may want to choose a brokerage platform, which can be daunting given so many options. This comparison chart can help aid you in choosing the right platform for your trading needs. 

IBIO on Benzinga Pro

Screenshot taken from Benzinga Pro on 10-10-2021

On October 10, 2021, Bio’s stock has an asking price of $1.34 with a current bid of $0.90 and a previous close of $0.944. Its session volume sits at 2.272 million, with an average 100-day volume of 3.362 million. iBio’s stock price has a 50-day moving average of 1.170 and a float of 217.281 million, accompanied by a short float of 15.860 million.  

Is iBio a Sound Investment to Add to your Portfolio? 

iBio stock is recommended for those who have extensive experience in the sector of healthcare stocks. Given iBio stock's performance, an experienced trader would be best suited for this stock due to the make-or-break nature of its performance based on its clinical trials. However, the stock is under the radar and may be worth further investigation for the prudent trader. 

Frequently Asked Questions